Evidence map›Paper›PMID 41221280›Full record

ArticleFrontiers in immunology2025

Senescent human fibroblasts have increased FasL expression and impair the tumor immune response.

Monica Cruz-Barrera, Joshua Dulong, Georgio Mansour Nehmo, Anthony Sonn, Gaël Moquin-Beaudry, Basma Benabdallah, Oanh Le, Christian Beauséjour

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Monica Cruz-BarreraCentre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada.
Joshua DulongCentre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada.
Georgio Mansour NehmoCentre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada.
Anthony SonnCentre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada.
Gaël Moquin-BeaudryDépartement de pharmacologie et physiologie Université de Montréal, Montréal, QC, Canada.
Basma BenabdallahCentre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada.
Oanh LeCentre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada.
Christian BeauséjourCentre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Syngeneic mouse tumor models have shown that senescence influences the tumor immune response in multiple ways, including the induction of an immunosuppressive microenvironment or the promotion of immune cell recruitment. Yet, the impact of senescence on the tumor immune response in a humanized setting remains largely unexplored. Methods: To address this question, we employed a combination cells co-culture models, tumor spheroids and mice bearing tumors immunogenic to human immune cells derived from the same donor. Results: We found that senescent fibroblasts exert a dual effect by enhancing the recruitment of immune cells into the tumor microenvironment while simultaneously promoting the apoptosis of T and NK cells. Mechanistically, we demonstrate that this apoptosis is primarily due to increased Fas ligand (FasL) expression on the surface of senescent fibroblasts. Increased FasL expression was observed on different human fibroblast cell lines in response to different senescence inducers with a particular robust effect in response to RAS-induced senescence. Deletion of FasL on fibroblasts was sufficient to prevent immune cell death and increase tumor cell killing in mice. Discussion: Our results identified the expression of FasL expression as a novel component of the senescent tumor microenvironment and highlight the importance of evaluating the impact of therapy-induced senescence in humanized models to understand and predict the outcome of cancer treatments.

Indexed as

Cellular SenescenceFas Ligand ProteinFibroblastsNeoplasmsAnimalsApoptosisCell Line, TumorCoculture TechniquesHumansKiller Cells, NaturalMiceTumor MicroenvironmentFASLG protein, humanFas Ligand Proteincell deathFasLimmune cellssenescencetumor

Identifiers

PMID41221280
PMCPMC12597918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.